Longâ€term safety and efficacy of sustained eculizumab paroxysmal nocturnal haemoglobinuria

British Journal of Haematology

162, 62-73

DOI: 10.1111/bjh.12347

Citation Report

#	Article	IF	Citations
1	Paroxysmal nocturnal hemoglobinuria and the age of therapeutic complement inhibition. Expert Review of Clinical Immunology, 2013, 9, 1113-1124.	1.3	8
2	Learnings from over 25 years of PNH experience: The era of targeted complement inhibition. Blood Reviews, 2013, 27, S1-S6.	2.8	5
3	A systematic review of eculizumab for atypical haemolytic uraemic syndrome (aHUS). BMJ Open, 2013, 3, e003573.	0.8	80
4	Blood consult: paroxysmal nocturnal hemoglobinuria and its complications. Blood, 2013, 122, 2795-2798.	0.6	7
5	Meningococcal disease and the complement system. Virulence, 2014, 5, 98-126.	1.8	189
6	Eculizumab Therapy in Children with Severe Hematopoietic Stem Cell Transplantationâ€“Associated Thrombotic Microangiopathy. Biology of Blood and Marrow Transplantation, 2014, 20, 518-525.	2.0	218
7	Treatment of Enterohemorrhagic Escherichia coliâ€“Induced Hemolytic Uremic Syndrome (eHUS). Seminars in Thrombosis and Hemostasis, 2014, 40, 508-516.	1.5	40
8	Successful discontinuation of eculizumab therapy in a patient with aHUS. Annals of Hematology, 2014, 93, 1423-1425.	0.8	19
9	Diagnosis and management of complement mediated thrombotic microangiopathies. Blood Reviews, 2014, 28, 67-74.	2.8	43
10	Hemoglobinuria paroxÃstica nocturna en una mujer de 86 aÃ±os. Revista Clinica Espanola, 2014, 214, e111-e113.	0.2	0
11	Complement and cytokine response in acute <scp>T</scp>hrombotic <scp>T</scp>hrombocytopenic <scp>P</scp>urpura. British Journal of Haematology, 2014, 164, 858-866.	1.2	49
12	Eculizumab for treating patients with paroxysmal nocturnal hemoglobinuria. The Cochrane Library, 2014, , CD010340.	1.5	13
14	Complement blockade with a C1 esterase inhibitor in paroxysmal nocturnal hemoglobinuria. Experimental Hematology, 2014, 42, 857-861.e1.	0.2	18
15	Efficacy and safety of eculizumab in children and adolescents with paroxysmal nocturnal hemoglobinuria. Pediatric Blood and Cancer, 2014, 61, 1544-1550.	0.8	35
16	Paroxysmal nocturnal hemoglobinuria: a single <scp>S</scp>panish center's experience over the last 40Âyr. European Journal of Haematology, 2014, 93, 309-319.	1.1	29
17	Eculizumab: a guide to its use in atypical haemolytic uraemic syndrome. Drugs and Therapy Perspectives, 2014, 30, 166-172.	0.3	1
18	Concerns about unapproved meningococcal vaccination for eculizumab therapy in Japan. Orphanet Journal of Rare Diseases, 2014, 9, 48.	1.2	3
19	New anti-complement drugs: not so far away. Blood, 2014, 123, 1975-1976.	0.6	13

#	Article	IF	Citations
20	Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria. Blood, 2014, 123, 2094-2101.	0.6	172
21	Paroxysmal nocturnal hemoglobinuria. Blood, 2014, 124, 2804-2811.	0.6	424
22	Complement in hemolytic anemia. Hematology American Society of Hematology Education Program, 2015, 2015, 385-391.	0.9	9
23	Increased eculizumab requirements during pregnancy in a patient with paroxysmal nocturnal hemoglobinuria: case report and review of the literature. Clinical Case Reports (discontinued), 2015, 3, 88-91.	0.2	16
24	Atypical haemolytic uraemic syndrome treated with the complement inhibitor eculizumab: the experience of the <scp>A</scp>ustralian compassionate access cohort. Internal Medicine Journal, 2015, 45, 1054-1065.	0.5	25
25	Complement inhibition for paroxysmal nocturnal hemoglobinuria: where we stand and where we are going. Expert Opinion on Orphan Drugs, 2015, 3, 691-704.	0.5	2
26	Complement in hemolytic anemia. Blood, 2015, 126, 2459-2465.	0.6	84
27	Assessing complement blockade in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab. Blood, 2015, 125, 775-783.	0.6	122
28	Dissecting complement blockade for clinic use. Blood, 2015, 125, 742-744.	0.6	12
29	Neutrophil activation and nucleosomes as markers of systemic inflammation in paroxysmal nocturnal hemoglobinuria: effects of eculizumab. Journal of Thrombosis and Haemostasis, 2015, 13, 2004-2011.	1.9	23
30	Eculizumab in Typical Hemolytic Uremic Syndrome (HUS) With Neurological Involvement. Medicine (United States), 2015, 94, e1000.	0.4	83
31	Use of Eculizumab in Patients With Allogeneic Stem Cell Transplant-Associated Thrombotic Microangiopathy. Transplantation, 2015, 99, 1953-1959.	0.5	110
32	Improvement of Renal Function by Long-Term Sustained Eculizumab Treatment in a Patient with Paroxysmal Nocturnal Hemoglobinuria. Case Reports in Hematology, 2015, 2015, 1-4.	0.3	1
33	Complement in therapy and disease. Molecular Immunology, 2015, 67, 117-130.	1.0	124
34	Spectrum and Management of Complement Immunodeficiencies (Excluding Hereditary Angioedema) Across Europe. Journal of Clinical Immunology, 2015, 35, 199-205.	2.0	40
35	Compstatin analog Cp40 inhibits complement dysregulation in vitro in C3 glomerulopathy. Immunobiology, 2015, 220, 993-998.	0.8	49
36	Paroxysmal Nocturnal Hemoglobinuria in Pregnancy. , 2015, , 327-342.		1
38	Paroxysmal Nocturnal Hemoglobinuria. Hematology/Oncology Clinics of North America, 2015, 29, 479-494.	0.9	52

#	Article	IF	Citations
39	Paroxysmal nocturnal hemoglobinuria revisited: news on pathophysiology, clinical course and treatment. Laboratoriums Medizin, 2015, 39, 87-96.	0.1	0
40	Update on paroxysmal nocturnal haemoglobinuria: on the long way to understand the principles of the disease. European Journal of Haematology, 2015, 94, 464-473.	1.1	27
41	The Need for Transparency and Efficiency in Reimbursement Decisions Relating to Drugs for Rare Diseases. Medical Decision Making, 2015, 35, 145-147.	1.2	0
42	Current and Future Pharmacologic Complement Inhibitors. Hematology/Oncology Clinics of North America, 2015, 29, 561-582.	0.9	30
43	Complement, a target for therapy in inflammatory and degenerative diseases. Nature Reviews Drug Discovery, 2015, 14, 857-877.	21.5	357
45	Paroxysmal nocturnal haemoglobinuria: to prednisone or not to prednisone? â€“ a case report of a patient previously treated with steroids for 15Âyrs and significant response on eculizumab. European Journal of Haematology, 2015, 95, 177-180.	1.1	3
46	Complement in Lupus Nephritis: New Perspectives. Kidney Diseases (Basel, Switzerland), 2015, 1, 91-99.	1.2	72
47	Importance of Transparency in Assessing the Feasibility of Modeling Rare Disease. Medical Decision Making, 2015, 35, 143-144.	1.2	1
48	Therapeutic drug monitoring of eculizumab: Rationale for an individualized dosing schedule. MAbs, 2015, 7, 1205-1211.	2.6	67
49	New perspectives on the thrombotic complications of haemolysis. British Journal of Haematology, 2015, 168, 175-185.	1.2	58
50	Successful use of eculizumab for treatment of an acute hemolytic reaction after <scp>ABO</scp>â€incompatible red blood cell transfusion. Transfusion, 2015, 55, 605-610.	0.8	27
51	Eculizumab treatment during pregnancy does not affect the complement system activity of the newborn. Immunobiology, 2015, 220, 452-459.	0.8	90
52	Anticomplement C5 therapy with eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Translational Research, 2015, 165, 306-320.	2.2	64
53	Eculizumab in the management of paroxysmal nocturnal hemoglobinuria: patient selection and special considerations. Therapeutics and Clinical Risk Management, 2016, Volume 12, 1161-1170.	0.9	26
54	Presentation and management of paroxysmal nocturnal hemoglobinuria: a single-center experience. Hematology Reports, 2016, 8, 6409.	0.3	2
55	Eculizumabâ˜†. , 2016, , .		0
56	Horse antiâ€thymocyte globulin and eculizumab as concomitant therapeutic approach in an aplastic paroxysmal nocturnal hemoglobinuria patient: go or noâ€go?. European Journal of Haematology, 2016, 97, 403-405.	1.1	6
57	Paroxysmal nocturnal hemoglobinuria in the era of complement inhibition. American Journal of Hematology, 2016, 91, 359-360.	2.0	4

#	Article	IF	Citations
58	Efficacy of ibrutinib in the treatment of <scp>B</scp>ingâ€“<scp>N</scp>eel syndrome. American Journal of Hematology, 2016, 91, E17-9.	2.0	48
59	Assessment of human antihuman antibodies to eculizumab after longâ€term treatment in patients with paroxysmal nocturnal hemoglobinuria. American Journal of Hematology, 2016, 91, E16-7.	2.0	13
60	Update on the diagnosis and management of paroxysmal nocturnal hemoglobinuria. Hematology American Society of Hematology Education Program, 2016, 2016, 208-216.	0.9	85
61	Anemia aplÃ¡sica. Hemoglobinuria paroxÃstica nocturna. Medicine, 2016, 12, 1159-1169.	0.0	0
62	Immunisation of the immunocompromised child. Journal of Infection, 2016, 72, S13-S22.	1.7	15
63	Complement in disease: a defence system turning offensive. Nature Reviews Nephrology, 2016, 12, 383-401.	4.1	427
64	Spanish consensus statement for diagnosis and treatment of paroxysmal nocturnal haemoglobinuria. Medicina ClÃnica (English Edition), 2016, 146, 278.e1-278.e7.	0.1	7
65	Interim analysis of post-marketing surveillance of eculizumab for paroxysmal nocturnal hemoglobinuria in Japan. International Journal of Hematology, 2016, 104, 548-558.	0.7	27
66	Generation of induced pluripotent stem cells as a potential source of hematopoietic stem cells for transplant in PNH patients. Annals of Hematology, 2016, 95, 1617-1625.	0.8	7
67	Eculizumab Dosing Intervals Longer than 17 Days May Be Associated with Greater Risk of Breakthrough Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria. Biological and Pharmaceutical Bulletin, 2016, 39, 285-288.	0.6	38
68	Overview of Laboratory Testing and Clinical Presentations of Complement Deficiencies and Dysregulation. Advances in Clinical Chemistry, 2016, 77, 1-75.	1.8	36
69	Small-molecule factor D inhibitors targeting the alternative complement pathway. Nature Chemical Biology, 2016, 12, 1105-1110.	3.9	68
70	New milestones ahead in complement-targeted therapy. Seminars in Immunology, 2016, 28, 208-222.	2.7	92
71	A comparative analysis of clinical characteristics of patients with paroxysmal nocturnal hemoglobinuria between Asia and Europe/America. International Journal of Hematology, 2016, 103, 649-654.	0.7	26
72	Therapeutic complement inhibition in complement-mediated hemolytic anemias: Past, present and future. Seminars in Immunology, 2016, 28, 223-240.	2.7	36
73	Impact of eculizumab treatment on paroxysmal nocturnal hemoglobinuria: a treatment versus noâ€treatment study. American Journal of Hematology, 2016, 91, 366-370.	2.0	110
75	Paroxysmal Nocturnal Hemoglobinuria: From Bench to Bed. Indian Journal of Hematology and Blood Transfusion, 2016, 32, 383-391.	0.3	5
76	Therapeutic control of complement activation at the level of the central component C3. Immunobiology, 2016, 221, 740-746.	0.8	41

#	Article	IF	Citations
77	Efficacy and safety of eculizumab in childhood atypical hemolytic uremic syndrome in Japan. Clinical and Experimental Nephrology, 2016, 20, 265-272.	0.7	22
78	An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatric Nephrology, 2016, 31, 15-39.	0.9	445
79	Patient stratification and therapy in atypical haemolytic uraemic syndrome (aHUS). Immunobiology, 2016, 221, 715-718.	0.8	6
80	Epidemiology in PNH: The PNH Global Registry. , 2017, , 99-107.		0
81	Paroxysmal Nocturnal Hemoglobinuria. , 2017, , .		1
82	Serologic response to meningococcal vaccination in patients with paroxysmal nocturnal hemoglobinuria (PNH) chronically treated with the terminal complement inhibitor eculizumab. Annals of Hematology, 2017, 96, 589-596.	0.8	23
83	Development of a disease-specific quality of life questionnaire for patients with aplastic anemia and/or paroxysmal nocturnal hemoglobinuria (QLQ-AA/PNH)â€"report on phases I and II. Annals of Hematology, 2017, 96, 171-181.	0.8	25
84	Complementopathies. Blood Reviews, 2017, 31, 213-223.	2.8	86
85	Management of thrombosis in paroxysmal nocturnal hemoglobinuria: a clinicianâ€™s guide. Therapeutic Advances in Hematology, 2017, 8, 119-126.	1.1	40
86	Biologic response modifiers: Indications, implications, and insights. Journal of Allergy and Clinical Immunology, 2017, 139, 1445-1456.	1.5	25
87	Therapeutic Inhibition of Complement: Well Worth the Risk. Trends in Pharmacological Sciences, 2017, 38, 503-505.	4.0	20
88	Complement: A primer for the coming therapeutic revolution. , 2017, 172, 63-72.		67
89	Paroxysmal nocturnal haemoglobinuria. Nature Reviews Disease Primers, 2017, 3, 17028.	18.1	299
90	New concepts on the therapeutic control of complement anaphylatoxin receptors. Molecular Immunology, 2017, 89, 36-43.	1.0	67
91	Eculizumab decreases the procoagulant activity of extracellular vesicles in paroxysmal nocturnal hemoglobinuria: A pilot prospective longitudinal clinical study. Thrombosis Research, 2017, 156, 142-148.	0.8	7
92	Clinical benefit of eculizumab in patients with no transfusion history in the International Paroxysmal Nocturnal Haemoglobinuria Registry. Internal Medicine Journal, 2017, 47, 1026-1034.	0.5	19
93	Strains Responsible for Invasive Meningococcal Disease in Patients With Terminal Complement Pathway Deficiencies. Journal of Infectious Diseases, 2017, 215, 1331-1338.	1.9	35
95	Presence of acute and chronic renal failure in patients with paroxysmal nocturnal hemoglobinuria: results of a retrospective analysis from the Spanish PNH Registry. Annals of Hematology, 2017, 96, 1727-1733.	0.8	15

#	Article	IF	Citations
96	Long lasting neutralization of C5 by SKY59, a novel recycling antibody, is a potential therapy for complement-mediated diseases. Scientific Reports, 2017, 7, 1080.	1.6	79
97	Atypical presentation of paroxysmal nocturnal hemoglobinuria treated by eculizumab. Medicine (United States), 2017, 96, e6403.	0.4	6
98	Meningococcal B Vaccine Failure With a Penicillin-Resistant Strain in a Young Adult on Long-Term Eculizumab. Pediatrics, 2017, 140, .	1.0	38
99	Interventions for atypical haemolytic uraemic syndrome. The Cochrane Library, 2017, , .	1.5	2
100	Combined inhibition of C5 and CD14 efficiently attenuated the inflammatory response in a porcine model of meningococcal sepsis. Journal of Intensive Care, 2017, 5, 21.	1.3	17
101	On the value of therapeutic interventions targeting the complement system in acute myocardial infarction. Translational Research, 2017, 182, 103-122.	2.2	13
102	Case 40-2017. New England Journal of Medicine, 2017, 377, 2581-2590.	13.9	2
103	Efficacy of eculizumab in paroxysmal nocturnal hemoglobinuria patients with or without aplastic anemia: prospective study of a Korean PNH cohort. Blood Research, 2017, 52, 207.	0.5	11
104	Acute myeloid leukemia and fatal Scedosporium prolificans sepsis after eculizumab treatment for paroxysmal nocturnal hemoglobinuria: a case report. Stem Cell Investigation, 2017, 4, 100-100.	1.3	5
105	Hepatotoxicity associated with eculizumab in a patient with atypical hemolytic uremic syndrome. Nefrologia, 2018, 38, 448-450.	0.2	8
107	Toward complement inhibition 2.0: Next generation anticomplement agents for paroxysmal nocturnal hemoglobinuria. American Journal of Hematology, 2018, 93, 564-577.	2.0	45
108	Autoimmune phenotypes in schizophrenia reveal novel treatment targets. , 2018, 189, 184-198.		30
109	CR1 gene polymorphisms in Chinese patients with paroxysmal nocturnal hemoglobinuria. Gene, 2018, 659, 149-154.	1.0	4
110	Safety and effectiveness of restrictive eculizumab treatment in atypical haemolytic uremic syndrome. Nephrology Dialysis Transplantation, 2018, 33, 635-645.	0.4	36
111	Post-eculizumab meningococcaemia in vaccinated patients. Clinical Microbiology and Infection, 2018, 24, 89-90.	2.8	11
112	Expanding horizons in complement drug discovery: challenges and emerging strategies. Seminars in Immunopathology, 2018, 40, 125-140.	2.8	49
113	Structure and characterization of a high affinity C5a monoclonal antibody that blocks binding to C5aR1 and C5aR2 receptors. MAbs, 2018, 10, 104-117.	2.6	29
114	Paroxysmal nocturnal haemoglobinuria testing in blood transfusion laboratories: do they go with the flow?. Transfusion Medicine, 2018, 28, 451-456.	0.5	2

#	Article	IF	Citations
115	Nephrotic-range proteinuria and brown urine in an 8-year-old girl: Questions. Pediatric Nephrology, 2018, 33, 1001-1002.	0.9	0
116	Nephrotic-range proteinuria and brown urine in an 8-year-old girl: Answers. Pediatric Nephrology, 2018, 33, 1003-1005.	0.9	0
117	Therapeutic challenges in pregnant women with paroxysmal nocturnal hemoglobinuria. Medicine (United States), 2018, 97, e12155.	0.4	7
118	Paroxysmal Nocturnal Hemoglobinuria Testing in Patients with Myelodysplastic Syndrome in Clinical Practiceâ€"Frequency and Indications. Current Oncology, 2018, 25, 391-397.	0.9	1
119	Renal involvement in paroxysmal nocturnal haemoglobinuria: a brief review of the literature. Revista Da AssociaÃ§Ã£o MÃ©dica Brasileira, 2018, 64, 1139-1146.	0.3	5
120	Nonimmune Hemolytic Anemia. , 2018, , 294-313.		0
121	Paroxysmal nocturnal hemoglobinuria: When delay in diagnosis and long therapy occurs. Hematology Reports, 2018, 10, 7523.	0.3	3
122	Diagnosis and management of PNH: Review and recommendations from a Belgian expert panel. European Journal of Haematology, 2018, 101, 737-749.	1.1	27
123	Complement-driven anemia: more than just paroxysmal nocturnal hemoglobinuria. Hematology American Society of Hematology Education Program, 2018, 2018, 371-376.	0.9	15
124	Ravulizumab (ALXN1210) in patients with paroxysmal nocturnal hemoglobinuria: results of 2 phase 1b/2 studies. Blood Advances, 2018, 2, 2176-2185.	2.5	65
125	Role of Complement in Cerebral Malaria. , 2018, , 65-90.		2
126	Design and preclinical characterization of ALXN1210: A novel anti-C5 antibody with extended duration of action. PLoS ONE, 2018, 13, e0195909.	1.1	150
127	Paroxysmal Nocturnal Hemoglobinuria. , 2018, , 415-424.		1
128	Meningococcal B Vaccine Immunogenicity in Children With Defects in Complement and Splenic Function. Pediatrics, 2018, 142, .	1.0	17
129	Eculizumab Bridging before Bone Marrow Transplant for Marrow Failure Disorders Is Safe and Does Not Limit Engraftment. Biology of Blood and Marrow Transplantation, 2018, 24, e26-e30.	2.0	16
130	Hepatotoxicity associated with eculizumab in a patient with atypical hemolytic uremic syndrome. Nefrologia, 2018, 38, 448-450.	0.2	5
131	Complement Activation in Malaria Immunity and Pathogenesis. , 2018, , .		0
132	The rational design of affinity-attenuated OmCI for the purification of complement C5. Journal of Biological Chemistry, 2018, 293, 14112-14121.	1.6	13

#	Article	IF	Citations
133	High sensitivity 8-color flow cytometry assay for paroxysmal nocturnal hemoglobinuria granulocyte and monocyte detections. Biomedical Reports, 2018, 8, 224-234.	0.9	2
134	Developments in anti-complement therapy; from disease to clinical trial. Molecular Immunology, 2018, 102, 89-119.	1.0	72
135	C3-mediated extravascular hemolysis in PNH on eculizumab: Mechanism and clinical implications. Seminars in Hematology, 2018, 55, 130-135.	1.8	25
136	Clinical promise of next-generation complement therapeutics. Nature Reviews Drug Discovery, 2019, 18, 707-729.	21.5	253
137	A review of thrombotic microangiopathies in multiple myeloma. Leukemia Research, 2019, 85, 106195.	0.4	17
138	Elevated Complement C3 and C4 Levels are Associated with Postnatal Pregnancy-Related Venous Thrombosis. Thrombosis and Haemostasis, 2019, 119, 1481-1488.	1.8	4
139	Anti-complement Treatment for Paroxysmal Nocturnal Hemoglobinuria: Time for Proximal Complement Inhibition? A Position Paper From the SAAWP of the EBMT. Frontiers in Immunology, 2019, 10, 1157.	2.2	133
140	Cholesterol Crystals Induce Coagulation Activation through Complement-Dependent Expression of Monocytic Tissue Factor. Journal of Immunology, 2019, 203, 853-863.	0.4	31
141	Eculizumab and Beyond: The Past, Present, and Future of Complement Therapeutics. Transfusion Medicine Reviews, 2019, 33, 256-265.	0.9	46
142	Compendium of current complement therapeutics. Molecular Immunology, 2019, 114, 341-352.	1.0	110
143	Complement Inhibitors in Clinical Trials for Glomerular Diseases. Frontiers in Immunology, 2019, 10, 2166.	2.2	86
144	Emerging Roles of Complement in Psychiatric Disorders. Frontiers in Psychiatry, 2019, 10, 573.	1.3	63
145	Ravulizumab: a novel C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria. Therapeutic Advances in Hematology, 2019, 10, 204062071987472.	1.1	50
146	Abdominal pain in combination with an unexplained hemolytic anemia are crucial signs to test for paroxysmal nocturnal hemoglobinuria: A case report. Clinical Case Reports (discontinued), 2019, 7, 175-179.	0.2	0
148	Hematopoietic Cell Transplantation for Paroxysmal Nocturnal Hemoglobinuria in the Age of Eculizumab. Biology of Blood and Marrow Transplantation, 2019, 25, 1331-1339.	2.0	17
149	Design and development of a disease-specific quality of life tool for patients with aplastic anaemia and/or paroxysmal nocturnal haemoglobinuria (QLQ-AA/PNH)â€"a report on phase III. Annals of Hematology, 2019, 98, 1547-1559.	0.8	18
150	The Extended Use of Eculizumab in Pregnancy and Complement Activationâ€"Associated Diseases Affecting Maternal, Fetal and Neonatal Kidneys-The Future Is Now?. Journal of Clinical Medicine, 2019, 8, 407.	1.0	25
151	Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10â€year pharmacovigilance analysis. British Journal of Haematology, 2019, 185, 297-310.	1.2	148

#	Article	IF	Citations
152	Hematopoietic Stem Cell Transplant and Cellular Therapy. , 2019, , 109-158.		1
153	Pharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumab. Clinical Pharmacokinetics, 2019, 58, 859-874.	1.6	82
155	Venous thromboembolism prophylaxis using the Caprini score. Disease-a-Month, 2019, 65, 249-298.	0.4	68
156	A pediatric neurologic assessment score may drive the eculizumab-based treatment of Escherichia coli-related hemolytic uremic syndrome with neurological involvement. Pediatric Nephrology, 2019, 34, 517-527.	0.9	24
157	Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitorâ€“experienced adult patients with PNH: the 302 study. Blood, 2019, 133, 540-549.	0.6	239
158	Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study. Blood, 2019, 133, 530-539.	0.6	227
159	How we treat paroxysmal nocturnal hemoglobinuria: A consensus statement of the Canadian PNH Network and review of the national registry. European Journal of Haematology, 2019, 102, 36-52.	1.1	41
160	Complement System: a Neglected Pathway in Immunotherapy. Clinical Reviews in Allergy and Immunology, 2020, 58, 155-171.	2.9	29
161	Intrinsic defects leading to increased erythrocyte destruction. , 2020, , 336-362.		0
162	Complement in neurological disorders and emerging complement-targeted therapeutics. Nature Reviews Neurology, 2020, 16, 601-617.	4.9	163
163	Risk factors for vascular liver diseases. Clinics and Research in Hepatology and Gastroenterology, 2020, 44, 410-419.	0.7	4
164	Beneficial effects of eculizumab regardless of prior transfusions or bone marrow disease: Results of the International Paroxysmal Nocturnal Hemoglobinuria Registry. European Journal of Haematology, 2020, 105, 561-570.	1.1	6
165	Insights into Potential Targets for Therapeutic Intervention in Epilepsy. International Journal of Molecular Sciences, 2020, 21, 8573.	1.8	22
166	Is the COVIDâ€19 thrombotic catastrophe complementâ€connected?. Journal of Thrombosis and Haemostasis, 2020, 18, 2812-2822.	1.9	53
167	Properdin Is a Key Player in Lysis of Red Blood Cells and Complement Activation on Endothelial Cells in Hemolytic Anemias Caused by Complement Dysregulation. Frontiers in Immunology, 2020, 11, 1460.	2.2	14
168	Consensus statement for diagnosis and treatment of paroxysmal nocturnal haemoglobinuria. Hematology, Transfusion and Cell Therapy, 2021, 43, 341-348.	0.1	14
169	Precision Medicine in Neurology: The Inspirational Paradigm of Complement Therapeutics. Pharmaceuticals, 2020, 13, 341.	1.7	15
170	Patient preferences and quality of life implications of ravulizumab (every 8 weeks) and eculizumab (every 2 weeks) for the treatment of paroxysmal nocturnal hemoglobinuria. PLoS ONE, 2020, 15, e0237497.	1.1	21

#	Article	IF	Citations
171	From Traditional to Targeted Immunotherapy in Myasthenia Gravis: Prospects for Research. Frontiers in Neurology, 2020, 11, 981.	1.1	19
172	Cost burden of breakthrough hemolysis in patients with paroxysmal nocturnal hemoglobinuria receiving ravulizumab versus eculizumab. Hematology, 2020, 25, 327-334.	0.7	14
173	The Inhibition of Complement System in Formal and Emerging Indications: Results from Parallel One-Stage Pairwise and Network Meta-Analyses of Clinical Trials and Real-Life Data Studies. Biomedicines, 2020, 8, 355.	1.4	10
174	Development of a patient-reported outcome questionnaire for aplastic anemia and paroxysmal nocturnal hemoglobinuria (PRO-AA/PNH). Orphanet Journal of Rare Diseases, 2020, 15, 249.	1.2	8
175	Results from multinational phase 3 studies of ravulizumab (ALXN1210) versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria: subgroup analysis of Japanese patients. International Journal of Hematology, 2020, 112, 466-476.	0.7	5
176	A review of the treatment landscape in paroxysmal nocturnal haemoglobinuria: where are we now and where are we going?. Therapeutic Advances in Rare Disease, 2020, 1, 263300402095934.	0.3	9
177	One-year efficacy and safety of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria naÃ¯ve to complement inhibitor therapy: open-label extension of a randomized study. Therapeutic Advances in Hematology, 2020, 11, 204062072096613.	1.1	24
178	Secondary myelodysplastic syndrome and leukemia in acquired aplastic anemia and paroxysmal nocturnal hemoglobinuria. Blood, 2020, 136, 36-49.	0.6	59
179	Update on immuneâ€mediated therapies for myasthenia gravis. Muscle and Nerve, 2020, 62, 579-592.	1.0	9
180	Nationwide study of paroxysmal nocturnal hemoglobinuria in South Korea: paradox of eculizumab. Annals of Hematology, 2020, 99, 1493-1503.	0.8	2
181	Cost-Utility Analysis of Ravulizumab Compared with Eculizumab in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria. Pharmacoeconomics, 2020, 38, 981-994.	1.7	16
182	Infectious Risks Associated with Biologics Targeting Janus Kinase-Signal Transducer and Activator of Transcription Signaling and Complement Pathway for Inflammatory Diseases. Infectious Disease Clinics of North America, 2020, 34, 271-310.	1.9	4
183	The case of eculizumab: litigation and purchases by the Brazilian Ministry of Health. Revista De Saude Publica, 2020, 54, 22.	0.7	7
184	Ravulizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Expert Opinion on Biological Therapy, 2020, 20, 227-237.	1.4	15
185	The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria. Blood, 2020, 135, 912-920.	0.6	73
186	Patients with paroxysmal nocturnal hemoglobinuria demonstrate a prothrombotic clotting phenotype which is improved by complement inhibition with eculizumab. American Journal of Hematology, 2020, 95, 944-952.	2.0	3
187	No evidence for hypogammaglobulinemia in patients with paroxysmal nocturnal hemoglobinuria (PNH) chronically treated with ravulizumab. PLoS ONE, 2020, 15, e0230869.	1.1	10
188	Characterization of breakthrough hemolysis events observed in the phase 3 randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria. Haematologica, 2020, 106, 230-237.	1.7	77

#	Article	IF	Citations
189	Oneâ€year outcomes from a phase 3 randomized trial of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria who received prior eculizumab. European Journal of Haematology, 2021, 106, 389-397.	1.1	24
190	Safety of current treatments for paroxysmal nocturnal hemoglobinuria. Expert Opinion on Drug Safety, 2021, 20, 171-179.	1.0	9
191	Antiphospholipid syndrome: Complement activation, complement gene mutations, and therapeutic implications. Journal of Thrombosis and Haemostasis, 2021, 19, 607-616.	1.9	45
192	Safety and effectiveness of eculizumab in Japanese patients with generalized myasthenia gravis: interim analysis of post-marketing surveillance. Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642110019.	1.5	20
193	The Benefits of Complement Measurements for the Clinical Practice. Methods in Molecular Biology, 2021, 2227, 1-20.	0.4	2
194	Complement as a Therapeutic Target in Systemic Autoimmune Diseases. Cells, 2021, 10, 148.	1.8	18
195	The potential of individualized dosing of ravulizumab to improve patientâ€friendliness of paroxysmal nocturnal haemoglobinuria treatment at reduced costs. British Journal of Clinical Pharmacology, 2021, 87, 3359-3363.	1.1	6
196	How I treat paroxysmal nocturnal hemoglobinuria. Blood, 2021, 137, 1304-1309.	0.6	63
197	Interventions for atypical haemolytic uraemic syndrome. The Cochrane Library, 2021, 2021, CD012862.	1.5	8
198	Therapeutic Targeting of the Complement System: From Rare Diseases to Pandemics. Pharmacological Reviews, 2021, 73, 792-827.	7.1	97
199	Efficacy and Safety of Eculizumab for Paroxysmal Nocturnal Hemoglobinuria: A Systematic Review and Meta-Analysis. Journal of Pediatric Hematology/Oncology, 2021, 43, 203-210.	0.3	7
200	Clinical characteristics and therapeutic outcomes of paroxysmal nocturnal hemoglobinuria patients in Turkey: a multicenter experience. Annals of Hematology, 2021, 100, 1667-1675.	0.8	0
201	Complement testing in the clinical laboratory. Critical Reviews in Clinical Laboratory Sciences, 2021, 58, 447-478.	2.7	4
202	Factor B inhibition for paroxysmal nocturnal haemoglobinuria. Lancet Haematology,the, 2021, 8, e309-e310.	2.2	0
203	Infections during eculizumab therapy in a Dutch population of patients with paroxysmal nocturnal haemoglobinuria. Clinical Microbiology and Infection, 2021, 27, 1534-1536.	2.8	0
204	Concept confirmation of the Treatment Administration Satisfaction Questionnaire (TASQ) in rare paroxysmal nocturnal hemoglobinuria. Journal of Patient-Reported Outcomes, 2021, 5, 45.	0.9	1
205	A small fragment of factor B as a potential inhibitor of complement alternative pathway activity. Immunobiology, 2021, 226, 152106.	0.8	3
206	Real-World Healthcare Resource Utilization (HRU) and Costs of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Receiving Eculizumab in a US Population. Advances in Therapy, 2021, 38, 4461-4479.	1.3	16

#	Article	IF	Citations
207	Phase 2 study of danicopan in patients with paroxysmal nocturnal hemoglobinuria with an inadequate response to eculizumab. Blood, 2021, 138, 1928-1938.	0.6	45
208	Randomized multicenter noninferiority phase III clinical trial of the first biosimilar of eculizumab. Annals of Hematology, 2021, 100, 2689-2698.	0.8	15
209	How we(â€™ll) treat paroxysmal nocturnal haemoglobinuria: diving into the future. British Journal of Haematology, 2022, 196, 288-303.	1.2	27
210	Elevated plasma concentration of complement factor C5 is associated with risk of future venous thromboembolism. Blood, 2021, 138, 2129-2137.	0.6	7
211	Eculizumab monotherapy for NMOSD: Data from PREVENT and its open-label extension. Multiple Sclerosis Journal, 2022, 28, 480-486.	1.4	32
212	Advancing therapeutic complement inhibition in hematologic diseases: PNH and beyond. Blood, 2022, 139, 3571-3582.	0.6	33
213	Comparative effectiveness of pegcetacoplan versus ravulizumab in patients with paroxysmal nocturnal hemoglobinuria previously treated with eculizumab: a matching-adjusted indirect comparison. Current Medical Research and Opinion, 2021, 37, 1913-1923.	0.9	13
214	No impact of Asian ethnicity on EORTC QLQ-C30 scores: Group differences and differential item functioning in paroxysmal nocturnal hemoglobinuria. Health and Quality of Life Outcomes, 2021, 19, 228.	1.0	2
215	Norm-based comparison of the quality-of-life impact of ravulizumab and eculizumab in paroxysmal nocturnal hemoglobinuria. Orphanet Journal of Rare Diseases, 2021, 16, 389.	1.2	6
216	Cost-Utility Analysis of Eculizumab for the Treatment of Paroxysmal Nocturnal Hemoglobinuria From the Perspective of the Brazilian Public Health System. Value in Health Regional Issues, 2021, 26, 113-125.	0.5	0
217	Clinical Effects of Eculizumab in PNH: Extravascular Hemolysis After Eculizumab Treatment. , 2017, , 283-295.		1
218	The renaissance of complement therapeutics. Nature Reviews Nephrology, 2018, 14, 26-47.	4.1	305
220	Pharmacokinetic and pharmacodynamic effects of ravulizumab and eculizumab on complement component 5 in adults with paroxysmal nocturnal haemoglobinuria: results of two phase 3 randomised, multicentre studies. British Journal of Haematology, 2020, 191, 476-485.	1.2	38
221	Recurrent cerebral ischaemic events in the setting of paroxysmal nocturnal haemoglobinuria. BMJ Case Reports, 2016, 2016, bcr2015213603.	0.2	3
222	Complement and inflammasome overactivation mediates paroxysmal nocturnal hemoglobinuria with autoinflammation. Journal of Clinical Investigation, 2019, 129, 5123-5136.	3.9	36
223	Netrin-1 Reduces Monocyte and Macrophage Chemotaxis towards the Complement Component C5a. PLoS ONE, 2016, 11, e0160685.	1.1	13
224	Characteristics of and meningococcal disease prevention strategies for commercially insured persons receiving eculizumab in the United States. PLoS ONE, 2020, 15, e0241989.	1.1	8
225	Notes from the Field: Meningococcal Disease in an International Traveler on Eculizumab Therapy â€" United States, 2015. Morbidity and Mortality Weekly Report, 2016, 65, 696-697.	9.0	9

#	Article	IF	Citations
226	Complement-mediated haemolysis and the role of blood transfusion in paroxysmal nocturnal haemoglobinuria. Blood Transfusion, 2015, 13, 363-9.	0.3	6
227	Terapeutisk komplementhemming â€“ fra eksperimentell til klinisk medisin. Tidsskrift for Den Norske Laegeforening, 2015, 135, 1745-1749.	0.2	7
228	Effect of a C1s Inhibitor on the Efficacy of Anti-Capsular Antibodies against Neisseria meningitidis and Streptococcus pneumoniae. ImmunoHorizons, 2019, 3, 519-530.	0.8	9
229	Successful eculizumab treatment of recurrent postpartum atypical hemolytic uremic syndrome after kidney transplantation. Clinical Nephrology Case Studies, 2015, 3, 8-13.	0.3	3
230	Hemolytic-Uremic Syndrome in childhood. Jornal Brasileiro De Nefrologia: Orgao Oficial De Sociedades Brasileira E Latino-Americana De Nefrologia, 2014, 36, 208-220.	0.4	5
231	Atypical Hemolytic Uremic Syndrome and Chronic Ulcerative Colitis Treated with Eculizumab. International Journal of Medical and Pharmaceutical Case Reports, 2015, 4, 105-112.	0.0	13
233	Soliris (Eculizumab): Discovery and Development. RSC Drug Discovery Series, 2014, , 401-418.	0.2	0
234	The complement system in lupus nephritis. F1000Research, 0, 4, 145.	0.8	2
235	Complement in hemolytic anemia. Hematology American Society of Hematology Education Program, 2015, 2015, 385-391.	0.9	0
237	Immediate Reactions To Monoclonal Antibodies In Clinical Hematology. International Journal of Medicine and Surgery, 2016, 3, 32-39.	0.0	0
238	Paroxysmal Nocturnal Haemoglobinuria in Pregnancy. International Journal of Pregnancy & Child Birth, 2016, 1, .	0.0	0
239	Future Strategies of Complement Inhibition in Paroxysmal Nocturnal Hemoglobinuria. , 2017, , 319-346.		0
240	Thrombophilia in PNH. , 2017, , 153-172.		0
241	Clinical Effects of Eculizumab in PNH. , 2017, , 271-282.		0
242	Clinical Management in PNH. , 2017, , 253-269.		0
243	A History of Research of PNH: Defining a Disease. , 2017, , 1-8.		0
244	Hematologic Complications Associated with HSCT. , 2018, , 283-299.		0
245	Eculizumab and Hematopoietic Stem Cell Transplantation for the treatment of Paroxysmal Nocturnal Hemoglobinuria associated to Aplastic Anemia. Clinical Case Reports and Reviews, 2018, 4, .	0.1	0

#	Article	IF	Citations
246	Paroxysmal nocturnal hemoglobinuria case presenting as cerebral venous sinus thrombosis. Journal of Surgery and Medicine, 0, , .	0.0	0
247	Off-Pump Coronary Revascularization Using Bilateral Internal Thoracic Arteries in A Patient with Paroxysmal Nocturnal Hemoglobinuria: A Case Report. Brazilian Journal of Cardiovascular Surgery, 2019, 34, 488-490.	0.2	0
248	Paroxysmal nocturnal hemoglobinuria: the path to diagnosis. Klinicist, 2019, 12, 56-61.	0.1	0
249	Successful treatment of noncirrhotic portal hypertension with eculizumab in paroxysmal nocturnal hemoglobinuria: A case report. World Journal of Hepatology, 2019, 11, 483-488.	0.8	0
250	Kinetic parameters of complement activation in patients with paroxysmal nocturnal hemoglobinuria during eculizumab therapy. Gematologiya I Transfuziologiya, 2020, 65, 126-137.	0.1	2
251	Pegcetacoplan versus Eculizumab in PNH. New England Journal of Medicine, 2021, 385, 1723-1726.	13.9	15
252	Paroxysmal nocturnal haemoglobinuria. , 2020, , 5348-5353.		0
253	Rare Hematological Disease of Paroxysmal Nocturnal Hemoglobinuria With Profound Implications for a Gastroenterologist: A Case Report and Literature Review. Cureus, 2020, 12, e8941.	0.2	2
254	Anti-Complement Treatment in Paroxysmal Nocturnal Hemoglobinuria: Where we Stand and Where we are Going. Translational Medicine @ UniSa, 2014, 8, 43-52.	0.8	14
255	Pesg PNH diagnosis, follow-up and treatment guidelines. American Journal of Blood Research, 2016, 6, 19-27.	0.6	14
257	Evaluation of clinical characteristics of patients with paroxysmal nocturnal hemoglobinuria treated with eculizumab in Turkey: a multicenter retrospective analysis. American Journal of Blood Research, 2021, 11, 279-285.	0.6	0
259	Hemolytic paroxysmal nocturnal hemoglobinuria: 20 years of medical progress. Seminars in Hematology, 2022, 59, 38-46.	1.8	4
260	Composite endpoint to evaluate complement inhibition therapy in patients with paroxysmal nocturnal hemoglobinuria. European Journal of Haematology, 2022, 108, 391-402.	1.1	4
261	Fighting fire with fire: The immune system might be key in our fight against Alzheimerâ€™s disease. Drug Discovery Today, 2022, 27, 1261-1283.	3.2	10
262	Paroxysmal nocturnal hemoglobinuria and vascular liver disease: Eculizumab therapy decreases mortality and thrombotic complications. American Journal of Hematology, 2022, 97, 431-439.	2.0	7
263	Long-term follow-up of patients with paroxysmal nocturnal hemoglobinuria treated with eculizumab: post-marketing surveillance in Japan. International Journal of Hematology, 2022, 115, 470-480.	0.7	4
264	Frequency of Paroxysmal Nocturnal Hemoglobinuria in Patients with Lymphoma. Middle Black Sea Journal of Health Science, 0, , .	0.2	0
265	Intertwined pathways of complement activation command the pathogenesis of lupus nephritis. Translational Research, 2022, 245, 18-29.	2.2	8

#	Article	IF	Citations
266	Pegcetacoplan for paroxysmal nocturnal hemoglobinuria. Blood, 2022, 139, 3361-3365.	0.6	6
268	Current Opinions on the Clinical Utility of Ravulizumab for the Treatment of Paroxysmal Nocturnal Hemoglobinuria. Therapeutics and Clinical Risk Management, 2021, Volume 17, 1343-1351.	0.9	2
269	Complement inhibition: A possible therapeutic approach in the fight against Covidâ€19. Reviews in Medical Virology, 2022, 32, e2316.	3.9	5
272	Real-World Eculizumab Dosing Patterns Among Patients with Paroxysmal Nocturnal Hemoglobinuria in a US Population. ClinicoEconomics and Outcomes Research, 2022, Volume 14, 357-369.	0.7	9
273	Longâ€term safety and efficacy of ravulizumab in patients with paroxysmal nocturnal hemoglobinuria: 2â€year results from two pivotal phase 3 studies. European Journal of Haematology, 2022, 109, 205-214.	1.1	19
274	The importance of terminal complement inhibition in paroxysmal nocturnal hemoglobinuria. Therapeutic Advances in Hematology, 2022, 13, 204062072210910.	1.1	10
276	Managing Fatigue in Patients with Paroxysmal Nocturnal Hemoglobinuria: A Patient-Focused Perspective. Journal of Blood Medicine, 0, Volume 13, 327-335.	0.7	6
277	Haploidentical vs matched sibling donor transplant for paroxysmal nocturnal haemoglobinuria: A multicenter study. Blood Cancer Journal, 2022, 12, .	2.8	1
278	Modulation of C5aâ€“C5aR1 signaling alters the dynamics of AD progression. Journal of Neuroinflammation, 2022, 19, .	3.1	15
279	Breakthrough Hemolysis in PNH with Proximal or Terminal Complement Inhibition. New England Journal of Medicine, 2022, 387, 160-166.	13.9	28
280	The treatment of atypical hemolytic uremic syndrome with eculizumab in pediatric patients: a systematic review. Pediatric Nephrology, 2023, 38, 61-75.	0.9	5
281	Inhibition of C3 with pegcetacoplan results in normalization of hemolysis markers in paroxysmal nocturnal hemoglobinuria. Annals of Hematology, 2022, 101, 1971-1986.	0.8	11
282	The role of the alternative pathway in paroxysmal nocturnal hemoglobinuria and emerging treatments. Expert Review of Clinical Pharmacology, 2022, 15, 851-861.	1.3	4
283	Low Rate of Clinically Evident Extravascular Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with a Complement C5 Inhibitor: Results from a Large, Multicenter, US Real-World Study. Journal of Blood Medicine, 0, Volume 13, 425-437.	0.7	3
284	Successful management of unstable angina in a ravulizumab-treated patient with paroxysmal nocturnal hemoglobinuria. Fukushima Journal of Medical Sciences, 2022, , .	0.1	0
285	Portal vein thrombosis as the first presentation of paroxysmal nocturnal hemoglobinuria. Drug Discoveries and Therapeutics, 2022, 16, 200-203.	0.6	1
286	Management of infection in PNH patients treated with eculizumab or other complement inhibitors: Unmet clinical needs. Blood Reviews, 2023, 58, 101013.	2.8	8
287	Dose optimalization of subcutaneous ravulizumab is predicted to yield significant savings and to improve patientâ€friendliness. British Journal of Clinical Pharmacology, 0, , .	1.1	0

#	Article	IF	Citations
288	Assessing the Impact of Prophylactic Eculizumab on Renal Graft Survival in Atypical Hemolytic Uremic Syndrome. Transplantation, 2023, 107, 994-1003.	0.5	6
289	Cost-effectiveness of ravulizumab compared with eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria in the Netherlands. European Journal of Health Economics, 0, , .	1.4	0
290	Biomarkers and laboratory assessments for monitoring the treatment of patients with paroxysmal nocturnal hemoglobinuria: Differences between terminal and proximal complement inhibition. Blood Reviews, 2023, 59, 101041.	2.8	3
291	Paroxysmal nocturnal hemoglobinuria: Where we stand. American Journal of Hematology, 2023, 98, .	2.0	3
292	Delayed Erythroid and Platelet Response to Eculizumab in Paroxysmal Nocturnal Haemoglobinuria â€“ A Case Report and Literature Review. European Medical Journal Hematology, 0, , 20-24.	0.0	0
293	The longâ€acting <scp>antiâ€C5</scp> ravulizumab results in <scp>C3</scp> binding to <scp>PNH</scp> red cells similar to its parental molecule eculizumab. British Journal of Haematology, 2023, 201, .	1.2	3
294	Comparative Effectiveness of Pegcetacoplan Versus Ravulizumab and Eculizumab in Complement Inhibitor-NaÃ¯ve Patients with Paroxysmal Nocturnal Hemoglobinuria: A Matching-Adjusted Indirect Comparison. Advances in Therapy, 2023, 40, 1571-1589.	1.3	4
295	Nationwide study of eculizumab in paroxysmal nocturnal hemoglobinuria: Evaluation of treatment indications and outcomes. European Journal of Haematology, 2023, 110, 648-658.	1.1	1
296	<scp>Longâ€term</scp> outcomes of patients with paroxysmal nocturnal hemoglobinuria treated with eculizumab in a <scp>realâ€world</scp> setting. European Journal of Haematology, 2023, 111, 84-95.	1.1	3
297	Paroxysmal nocturnal hemoglobinuria: Where are we going. American Journal of Hematology, 2023, 98, .	2.0	4
299	Atypical Hemolytic Uremic Syndrome. , 2023, , 605-639.		0
300	Characterization of multivalent complexes formed in the presence of more than one conventional antibody to terminal complement component C5. PLoS ONE, 2023, 18, e0284502.	1.1	1
301	Changes in Hematologic Lab Measures Observed in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with C5 Inhibitors, Ravulizumab and Eculizumab: Real-World Evidence from a US Based EMR Network. Hematology Reports, 2023, 15, 266-282.	0.3	2